Results 71 to 80 of about 12,566,431 (163)

Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes. [PDF]

Res Pract Thromb Haemost, 2023
Iorio A, MacDonald V, Caillaud A, Luckevich MD, Christoffersen P, Matino D, Keepanasseril A, Iserman E, Germini F, Bentley A, Poon MC.   +10 more
europepmc   +1 more source

Systemic delivery of factor IX messenger RNA for protein replacement therapy

Proceedings of the National Academy of Sciences of the United States of America, 2017
Suvasini Ramaswamy, Nina Tonnu, K. Tachikawa, P. Limphong, J. Vega, P. Karmali, P. Chivukula, I. Verma   +7 more
semanticscholar   +1 more source

Carbonic anhydrase IX downregulation linked to disruption of HIF-1, NFκB and STAT3 pathways as a new mechanism of ibuprofen anti-cancer effect.

PLoS ONE
Numerous studies have highlighted the anti-cancer effects of nonsteroidal anti-inflammatory drugs (NSAIDs), although the underlying mechanisms remain unclear.
Katarina Grossmannova, Petra Belvoncikova, Barbora Puzderova, Veronika Simko, Lucia Csaderova, Jaromir Pastorek, Monika Barathova   +6 more
doaj   +1 more source

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX

Haemophilia, 2017
Miguel A. Escobar, Ramin Tehranchi, F. A. Karim, U. Çalişkan, P. Chowdary, T. Colberg, Paul Giangrande, A. Giermasz, M. E. Mancuso, M. Serban, Woei Tsay, Johnny Mahlangu   +11 more
semanticscholar   +1 more source

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

Molecular Therapy: Methods & Clinical Development, 2019
Hemophilia A (HA) and hemophilia B (HB) are X-linked bleeding disorders due to inheritable deficiencies in either coagulation factor VIII (FVIII) or factor IX (FIX), respectively.
Benjamin J. Samelson-Jones, Valder R. Arruda   +1 more
doaj  

Estudio familiar de las hemofilias A y B: 5 años de experiencia en la detección de portadoras Family study of hemophilia A and B: 5 years of experience in carrier detection

Revista Cubana de Hematología, Inmunología y Hemoterapia, 2010
La hemofilia se caracteriza por ser una enfermedad congénita del trastorno de la coagulación y constituye un desorden recesivo ligado al cromosoma X. El estudio molecular se realiza por estudios indirectos por ser causada por mutaciones heterogéneas en ...
Yaixa Piloto Roque, Teresa Collazo Mesa, Manuel Gómez Martínez, Yadira Hernández Pérez, Yulemi Gónzalez Quesada, Ilienis Giraldo Rico, Lídice Reyes Navarro   +6 more
doaj  

Prothrombin Time and Coagulation Factor IX as Hemostatic Risk Markers for Legg- Calvé-Perthes Disease. [PDF]

Clin Appl Thromb Hemost, 2023
Hernández-Zamora E, Rodríguez-Olivas AO, Rosales-Cruz E, Galicia-Alvarado MA, Zavala-Hernández C, Reyes-Maldonado E.   +5 more
europepmc   +1 more source

Overestimation of N‐glycoPEGylated factor IX activity in a one‐stage factor IX clotting assay owing to silica‐mediated premature conversion to activated factor IX

Journal of Thrombosis and Haemostasis, 2016
P. Rosén, S. Rosén, M. Ezban, E. Persson   +3 more
semanticscholar   +1 more source

Modified Factor VIII and Factor IX recombinant products

HemaSphere, 2018
Elena Santagostino, Maria Elisa Mancuso
doaj   +1 more source

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments. [PDF]

Semin Thromb Hemost, 2023
Bowyer AE, Gosselin RC.
europepmc   +1 more source